Treatment of Severe Male Infertility - Predictive Factors (Imaging)
Launched by TURKU UNIVERSITY HOSPITAL · Oct 10, 2016
Trial Information
Current as of May 05, 2025
Completed
Keywords
ClinConnect Summary
Sperm recovery rate in non-obstructive azoospermia (NOA) men is 43% in Turku University Hospital, depending on the diagnosis leading to NOA. To date, there are no known parameters known to differentiate between successful and unsuccessful sperm recovery.
MRI is performed on men prior to the operation, and the objective is to compare the functional parameters assessed by magnetic resonance imaging between the group of men with positive and the men with negative sperm recovery in testicular microdissection sperm extraction (MD-TESE).
Gender
MALE
Eligibility criteria
- Inclusion Criteria:
- • non obstructive azospermia
- Exclusion Criteria:
- • malignancy
- • contraindication for fertility treatment
About Turku University Hospital
Turku University Hospital (TYKS) is a leading academic medical center located in Turku, Finland, renowned for its commitment to advancing healthcare through innovative research and clinical excellence. As a key institution within the University of Turku, TYKS integrates cutting-edge medical education with state-of-the-art clinical services, offering a broad spectrum of specialized care. The hospital actively participates in clinical trials, facilitating the translation of scientific discoveries into practical treatments, and enhancing patient outcomes. With a multidisciplinary approach and a focus on collaboration, TYKS aims to contribute significantly to the global medical community through its rigorous research initiatives and commitment to patient-centered care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Turku, , Finland
Turku, , Finland
Patients applied
Trial Officials
Antti Perheentupa, MD,PhD
Study Director
Turku University Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials